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Abstract
Machado-Joseph disease or Spinocerebellar ataxia type 3 is a progressive fatal neurodegenerative disorder caused by the
polyglutamine-expanded protein ataxin-3. Recent studies demonstrate that RNA interference is a promising approach for
the treatment of Machado-Joseph disease. However, whether gene silencing at an early time-point is able to prevent the
appearance of motor behavior deficits typical of the disease when initiated before onset of the disease had not been
explored. Here, using a lentiviral-mediated allele-specific silencing of mutant ataxin-3 in an early pre-symptomatic cerebellar
mouse model of Machado-Joseph disease we show that this strategy hampers the development of the motor and
neuropathological phenotypic characteristics of the disease. At the histological level, the RNA-specific silencing of mutant
ataxin-3 decreased formation of mutant ataxin-3 aggregates, preserved Purkinje cell morphology and expression of
neuronal markers while reducing cell death. Importantly, gene silencing prevented the development of impairments in
balance, motor coordination, gait and hyperactivity observed in control mice. These data support the therapeutic potential
of RNA interference for Machado-Joseph disease and constitute a proof of principle of the beneficial effects of early allele-
specific silencing for therapy of this disease.
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Introduction
Machado-Joseph disease (MJD) or Spinocerebellar ataxia type 3
(SCA3) is a dominant fatal inherited disorder of the central
nervous system (CNS) caused by overrepetition of the CAG
trinucleotide in the coding region of the MJD1/ATXN3 gene,
which encodes the ataxin-3 protein (Atx3) [1]. In this work we
characterize the effects of mutant ataxin-3 silencing on MJD-
associated motor behavior and neuropathological abnormalities in
a pre-symptomatic cerebellar mouse model by co-injecting
lentiviral vectors encoding for the silencing short hairpins RNAs
and vectors encoding for mutant ataxin-3. We show that early
mutant ataxin-3 silencing abolishes the appearance of balance and
motor coordination deficits, ataxic gait and histological hallmarks
of the disease.
MJD belongs to a wide group of similar disorders designated
polyglutamine diseases [2]. MJD is characterized by diverse
clinical presentation, particularly cerebellar ataxia, along with
other symptoms such as peripheral neuropathy, bulging eyes,
ophthalmoplegia, dystonia, nystagmus and fasciculations [3–6]. A
common hallmark of the disease is the accumulation of
abnormally misfolded protein, typically in the form of intranuclear
neuronal inclusions [7] in affected brain regions, such as afferent
and efferent cerebellar systems, substantia nigra, cranial nerve
motor nuclei [5] and striatum [8–11]. MJD is the most common
ataxia worldwide [12] and similarly to most other polyglutamine
diseases no treatment is available.
In the last years, the strategy of gene silencing by RNA
interference (RNAi) has been proposed to knock-down the
expression of mutant genes in order to rescue the phenotype of
dominant disorders, including polyglutamine diseases [13]. Other
strategies have been proposed to improve mutant protein
clearance and mitigate its toxic effects [14–16], but within the
molecular cascade that leads ultimately to neuronal dysfunction
and cell death, none of these acts as early as RNA interference,
which we and others have shown to be effective to treat several
diseases including MJD [17–21]. However, for the specific case of
MJD, in vivo studies testing the ability of gene silencing initiated at
an early stage to prevent the appearance and progression of motor
behavior abnormalities were missing. This is particularly relevant
in MJD as patient’s genotyping could allow initiation of treatment
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e100086
Early Gene Silencing Alleviates MJD
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e100086
before the appearance of the first symptoms. The lentiviral mouse
model here used is particularly suited for this specific study as it
allows initiation of the knock-down of mutant ataxin-3 at an early
time-point before onset of symptoms.
One important issue to consider is whether allele-specific
silencing of mutant ataxin-3 or generalized silencing of both
alleles of the protein, wild-type and expanded/mutant should be
done. The ataxin-3 protein has a de-ubiquitinating enzyme
activity [22,23] and it has also been linked to aggresome formation
[24], endoplasmatic reticulum-associated degradation [25], cyto-
skeleton network [26], among other roles. Therefore, although
knock-out mice for ataxin-3 have no major abnormalities [27,28]
and generalized silencing of ataxin-3 in the context of MJD has
proved to be safe and effective [29], here we used the more
cautious approach of allele-specific silencing for the mutant ataxin-
3. This strategy takes advantage of a single nucleotide polymor-
phism, which can discriminate the mutant allele in approximately
70% of MJD patients [17–21,30].
We demonstrate therapeutic efficacy of the gene silencing
approach in this pre-symptomatic cerebellar model in abolishing
the appearance of the representative MJD gait, balance and motor
coordination abnormalities, as well as neuropathology, supporting
the beneficial effects of this strategy as a therapeutic approach for
MJD.
Results
Allele-specific silencing of mutant ataxin-3 prevents
motor coordination and gait deficits
In this study, to explore the outcome of mutant ataxin-3 gene
silencing in MJD motor phenotype and neuropathology, lentiviral
vectors encoding RNA interference transcripts were co-injected
with the human full-length mutant ataxin-3 in the cerebellum of
wild-type mice (Figure S1 in File S1). To ensure the specific
silencing of mutant ataxin-3, we used short-hairpin RNAs
(shRNA) specifically targeting the mutant ataxin-3 allele (shAtx3,
n=8), carrying a previously characterized single nucleotide
polymorphism [18]. A similar group of mice injected with a
control shRNA sequence against green fluorescent protein
(shGFP, n=7) was used as control. To analyze whether mutant
ataxin-3 silencing would prevent appearance of a MJD- typical
motor phenotype [31], motor behavior was assessed every 2 weeks
during 10 weeks post-injection (Fig. 1 a).
In the accelerating rotarod test (acceleration from 4 to 40 rpm
in 5 min) (Fig. 1 b and Figure S2 in File S1), mice injected with
shAtx3 (Fig. 1 b); closed diamonds, n=8) exhibited a performance
that was not significantly different from wild-type non-injected
animals (open squares) at any time-point. In opposition mice
injected with shGFP (control, Fig. 1 b, open circles, n=7),
displayed a significant loss of performance already at 4 weeks post-
injection, being statistically different at longer time-points (Fig. 1
b; n=7–8; T8 and T10: *P,0.05). In fact, while the control-
treated MJD mice performance aggravated along time, shAtx3-
treated mice had a constant and normal performance during the
whole period of the test, and similar to wild-type non-injected mice
performance (Figure S2 in File S1). These data suggest that gene
silencing is able to hamper the appearance of balance and motor
coordination abnormalities, common symptoms observed in MJD.
Another symptom frequently observed in MJD patients and
MJD mouse models is the presence of gait ataxia [31–35]. To
access if mutant ataxin-3 silencing was able to impede the
development of an ataxic gait, footprint quantitative analysis was
performed (Fig. 1 c–f). The footprint patterns revealed that
shAtx3- injected mice had a significantly increased stride length
relative to shGFP-injected mice starting at 6 weeks post-injection
(Fig. 1 c; n=7–8; T6: *P,0.05; T8: ***P,0.001; T10: **P,
0.01). The distance between the front and hind footprint
placement or footprint overlap was shorter in shAtx3 mice relative
to shGFP, starting at 6 weeks post-injection (Fig. 1 d; n=7–8; T6:
*P,0.05; T8: **P,0.01; T10: *P,0.05), and the width between
left and right footstep of hind (Fig. 1 e; n=7–8; T6: **P,0.01;
T8: *P,0.05; T10: **P,0.05) and front paws (Fig. 1 f; n=7–8;
T8: *P,0.05; T10: *P,0.05), showed that shAtx3-injected mice
had a narrow hind and front base width relative to control
(shGFP). The footprint patterns quantitative analysis revealed that
shAtx3-injected mice revealed similar values to non-injected mice
in all measurements [31]. Altogether this data show that mutant
ataxin-3 gene silencing is efficient in preventing the appearance of
an ataxic gait.
Allele specific silencing reduces the hyperactivity
observed in the MJD mouse model
In view of these results we next investigated the activity pattern
of RNA interference-injected MJD mice. Explorative behavior
and general activity measurements were analyzed by the open field
test before the injection, and 4, 8 and 10 weeks post-injection
during 40 minutes per time point (Fig. 2). Allele-specific silencing
of mutant ataxin-3 reduced the hyperactivity that characterizes
mice upon overexpression of mutant ataxin-3 in the cerebellum
[31]. Thus, these animals traveled less distance than control-
injected animals (Fig. 2 a; n=8; T8: *P,0.05; T10: **P,0.01),
and spent more time resting (Fig. 2 b; n=8; T8: *P,0.05; T10:
*P,0.05), with a similar pattern of non-injected control mice [31].
In addition, by focusing the analysis in the last time point (Fig. 2 c–
Figure 1. Allele specific silencing of mutant ataxin-3 prevents the appearance of balance and motor coordination abnormalities. (a)
Time course of mice behavior tests: rotarod performance test, footprints patterns analysis and activity box monitoring. (b) Rotarod test. Mice were
placed in a rotarod accelerating from 0 to 40 r.p.m. in 5 min. Mice co-injected with Atx3 MUT and shAtx3 (closed circles, n= 8) showed an
improvement performance relative to mice co-injected with Atx3 MUT and shGFP (control) (open circles, n=7), especially at 8 and 10 weeks post-
injection. Wild-type non-injected mice are represented as WT (n= 8). Values are expressed as mean 6 SEM. *P,0.05 (2-way ANOVA Bonferroni post-
test). (c–f) Footprint analysis of shAtx3 and shGFP-treated Atx3 MUT mice. (c) Stride length. Mice injected with RNA interference against mutant
ataxin-3 (MUT+shAtx3) have an increased stride length relative to control (MUT+shGFP) starting at 6 weeks post-injection. Values are expressed as
mean 6 SEM. *P,0.05, **P,0.01, ***P,0.001 (2-way ANOVA Bonferroni post-test). (d) Footprint overlap. The distance between the front and hind
footprint placement or overlap is reduced in shAtx3-injected mice relative to control, starting at 6 weeks post-injection. Values are expressed as mean
6 SEM. *P,0.05, **P,0.01 (2-way ANOVA Bonferroni post-test). (e) Hind base width. The shAtx3-injected mice have a narrow hind base width relative
to control, starting at 6 weeks post-injection. Values are expressed as mean 6 SEM. *P,0.05, **P,0.01 (2-way ANOVA Bonferroni post-test). (f) Front
base width. The shAtx3-injected mice have a narrow front base width relative to control, starting at 8 weeks post-injection. Values are expressed as
mean 6 SEM. *P,0.05 (2-way ANOVA Bonferroni post-test). In general the patterns clearly differ, showing that shAtx3-injected mice display longer
strides, evenly spaced and accurately positioned footprints when compared to control-treated MJD mice.
doi:10.1371/journal.pone.0100086.g001
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f, 10 weeks post-injection) we could observe that shAtx3-expressing
mice travelled consistently less than shGFP mice during the whole
40 minutes of the test (Fig. 2 c). This difference was already
present in the first 10 minutes of the analysis (Fig. 2 d; n=7; T2:
*P,0.05; T8: *P,0.05; T9: *P,0.05; T10: ***P,0.001),
correlating with a decrease in the explorative behavior of the
shAtx3-expressing mice. Furthermore, by dividing the analysis of
this first 10 minutes in 2 different arena zones, periphery/zone1
and center/zone 2, interesting results were obtained (Fig. 2 e and
f). The periphery of the arena is a comfort zone, correlating with
shelter, while the center of the arena is an unprotected zone,
correlating with reduced anxiety and fear [36,37]. Mice expressing
shAtx3 travelled less in the periphery (Fig. 2 e; n=8; T8: *P,
0.05; T9: *P,0.05; T10: ***P,0.001) and in the center (Fig. 2 f;
n=8; T2: **P,0.01; T4: *P,0.05; T6: *P,0.05; T10: ***P,
0.001; Figure S3 in File S2), as compared to control mice.
Interestingly, larger differences were observed in the center of the
arena, with shAtx3 mice travelling substantially less in this zone
when compared to the periphery. Overall these results suggest that
control mice displayed a hyperactive phenotype associated with a
reduced anxiety as compared to non-injected wild-type mice [31],
which was prevented upon mutant ataxin-3 silencing.
Expression of short-hairpin RNAs targeting mutant
ataxin-3 in the cerebellum of a lentiviral-based MJD
mouse model decreases the formation of intranuclear
inclusions
An important hallmark of MJD is the presence of intranuclear
aggregates or inclusions in the affected areas [7]. Histological
analysis of the brain showed the presence of intranuclear mutant
ataxin-3 inclusions in both groups, mainly present in the molecular
layer of the cerebellar cortex (Fig. 3; Figure S4 in File S2).
Nevertheless, while shGFP-expressing cells (Fig. 3A: a–h), revealed
by lacZ reporter gene (Fig. 3A: c and g), also exhibited mutant
ataxin-3 (Fig. 3A: b and f); shAtx3-expressing cells (Fig. 3A: i–p)
did not stain for mutant ataxin-3 protein (Fig. 3A: j and n) in cells
transduced with the ataxin-3-targeting shRNAs, and therefore
positive for the lacZ reporter gene (Fig. 3A: k and o). This
observation was further confirmed by quantitative analysis of the
mean number of aggregates present in both groups, which
revealed a significant reduction in the number of cells presenting
mutant ataxin-3 aggregates in shAtx3-injected mice as compared
to controls (Fig. 3B; n=6; 202.9640.56 versus 1004637.77 in
control; ***P,0.001).
We further investigated the effects of mutant ataxin-3 silencing
by western blot analysis of protein and real-time PCR of mRNA
levels, in the mice cerebella (Fig. 4A). Probing the membrane with
the 1H9 antibody, a marker for ataxin-3, revealed a robust and
significant decrease in the levels of soluble (52%) and aggregated
(66%) mutant ataxin-3 in the animals co-injected with shAtx3
compared to controls co-injected with shGFP (n=3; aggregates at
the upper level of the running and stacking gels Fig. 4B :
0.29760.05 versus 0.87860.10 in control, P=0.0073, normaliz-
ing with tubulin; and soluble protein levels Fig. 4C : 0.54360.02
versus 1.12560.08 in control, P=0.0027, normalizing with
tubulin), whereas no difference was found between groups in the
endogenous ataxin-3 levels (not shown). Moreover, the levels of
ataxin-3 mRNA (Fig. 4D) were also strongly reduced in the
animals co-injected with shAtx3 compared to control ones (n=3;
Fig. 4D: 8.43261.255 versus 10061.528 in control, P,0.0001,
normalizing with hprt endogenous mRNA levels).
Silencing of mutant ataxin-3 mediates neuroprotection
to Purkinje cells
A common hallmark of polyglutamine diseases, including MJD
is the loss of neuronal markers expression in affected regions
[11,32,38]. Therefore, we next evaluated if the RNA interference
treatment would be neuroprotective regarding mutant ataxin-3-
associated loss of neuronal markers.
Fluorescent analysis of dopamine- and cyclic AMP-regulated
phosphoprotein of molecular weight 32 KDa (Fig. 5A, upper
panel: a–b) revealed that shAtx3-expressing mice displayed
Purkinje cells with a normal morphology and immunoreactivity
for DARPP-32 (arrows) while in control-treated mice Purkinje cells
were shrunken and faintly immunoreactive to the DARPP-32
antibody (arrow heads). Quantitative analysis of the DARPP-32
immunoreactivity showed a preservation of DARPP-32 immuno-
reactivity in cerebellar sections of shAtx3-injected mice as
compared to controls (Fig. 5 B; n=5; 1.6360.074 versus
0.7660.038 in control; ***P,0.001). Analysis of the calbindin
D-28K staining (Fig. 5A, lower panel: c–d) revealed a much
stronger immunoreactivity for calbindin in Purkinje cells of
shAtx3-expressing mice as compared to controls. This observation
was further confirmed by quantitative analysis (Fig. 5C; n=5;
2.88960.1182 versus 2.10360.1591 in control; **P,0.01). These
data indicate that silencing of mutant ataxin-3 expression blocks
the progression of neuronal dysfunction.
To access if RNA interference-treatment was able to impede
neurodegeneration and cell death, analysis of cresyl violet (Fig. 6A)
and tunnel staining (Fig. 6E) was performed. Mice expressing
shAtx3 revealed to have a significant increased number of Purkinje
cells and overall cellular integrity as compared to control treated
(Fig. 6A: a–d), which was further confirmed by quantitative
analysis (Fig. 6B; n=4; 11.8561.22 versus 7.0060.41 in control;
**P,0.01). Moreover there was also a preservation of molecular
layer thickness (Fig. 6C; n=5; 145.167.21 versus 116.365.02 in
control; *P,0.05) as well as of the granular layer thickness
Figure 2. Allele specific silencing of mutant ataxin-3 reduces hyperactivity. (a, b) Analysis of the activity in the last 30 minutes (one zone).
(a) Distance travelled. Mice injected with shAtx3 travelled less than control-injected mice starting at 8 weeks post-injection. Values are expressed as
mean6 SEM. *P,0.05, ** P,0.001 (2-way ANOVA Bonferroni post-test). (b) Time spent on resting. Mice injected with shAtx3 spent more time resting
than control-injected mice starting at 8 weeks post-injection. Values are expressed as mean 6 SEM. *P,0.05 (2-way ANOVA Bonferroni post-test). (c)
Plots of the moved track in the arena during the 40 minutes in the activity box at 10 weeks post-injection showed a clear difference between animals
injected with shAtx3 and control mice. (d–f) Analysis minute-by-minute of distance travelled in the last time-point (10 weeks post-injection). (d)
Distance travelled in the entire arena (one zone) during the first 10 minutes of the test. Values are expressed as mean6 SEM. *P,0.05, ***P,0.001 (2-
way ANOVA Bonferroni post-test). (e) Analysis of the periphery of the arena (zone 1) during the first 10 minutes. This zone is associated with comfort
and shelter. (f) Analysis of the center of the arena (zone 2) during the first 10 minutes. This zone is associated with reduced anxiety and fear. Mice
injected with shAtx3 displayed a reduced hyperactivity relative to control, preferring the comfort zone (zone 1) relative to the center (zone 2). Taken
together the significant differences were evident almost in all time points. Values are expressed as mean 6 SEM. *P,0.05, **P,0.01, ***P,0.001 (2-
way ANOVA Bonferroni post-test).
doi:10.1371/journal.pone.0100086.g002
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(Fig. 6D; n=5; 150.362.69 versus 134.161.80; **P,0.01) in
mice injected with shAtx3 compared to controls.
Consistent with these results, the Tunel assay also allowed
detection of apoptotic cells in transduced areas of the molecular
layer, in the control animals co-injected with shGFP in opposition
to animals co- injected with shAtx3, which did not present tunel
positive cells (Fig. 6E: e–j). Furthermore, FluoroJade-B staining
revealed a consistently higher fluorescence consistent with
neuronal degeneration in the molecular layer of the cerebellum
in the control animals co-injected with shGFP (Figure S5 in File
S2). Finally, Golgi staining revealed loss of dendritic arborizations
in control animals compared to animals injected with shAtx3
(Figure S5 in File S2). Overall these data show that mutant ataxin-
3 silencing prevents the appearance of the neurodegenerative
pattern that is typical of this MJD model.
Discussion
In this study, we investigated whether allele-specific gene
silencing initiated before onset of symptoms would alleviate
MJD. For this purpose we used an experimental paradigm
involving simultaneous injection of lentiviral vectors encoding for
the mutant ataxin-3 and for the shRNA sequences in the mouse
cerebella, in this way mimicking a gene silencing therapy initiated
at a pre-symptomatic stage. We found that this strategy is able to
suppress or drastically reduce the development of motor impair-
ments and neuropathological abnormalities representative of
MJD.
The RNAi strategy has been proposed as potential therapy to
down-regulate the expression of mutant genes and halt the
progression of different autosomal dominant neurodegenerative
diseases. To date its efficacy has been proved in several pre-clinical
rodent trials for diseases such as Huntington’s disease (HD)
[39,40], familial forms of amyotrophic lateral sclerosis (ALS)
[41,42] and spinocerebellar ataxia type 1 (SCA1) [43] as well as in
familial forms of Alzheimer disease (AD) [44]. Among the
important concerns relative to RNAi therapy is the development
of allele-specific approaches in order to selectively target the
mutant allele without inhibiting the corresponding wild-type allele.
This concern is of particular importance in diseases where the
knockdown of wild-type allele has proved to be toxic; nevertheless
even when an obvious toxicity is not present, given the potential
unknown side effects of long-term silencing of wild-type proteins,
selective strategies offer a better therapeutic solution [45].
In previous work, we and others have shown that both allele-
specific [18,19] and undiscriminating silencing [20,21,29] were
effective strategies for alleviating striatal neuropathology of MJD.
Here we show that early allele-specific silencing of mutant ataxin-3
is able not only to impede the development of mutant ataxin-3
aggregated and associated neuronal dysfunction within the
cerebellum but also to robustly prevent the progression of balance
and motor coordination deficits measured by the accelerated
rotarod test as well as gait analysis of footprints. Despite the
limitations of the experimental paradigm, as simultaneous
injection of vectors encoding for mutant ataxin-3 and for the
silencing sequences (shAtx3) may prevent the levels of mutant
ataxin-3 from reaching the levels found in controls, our data
constitutes a proof-of-principle for initiation of therapy before
onset of the disease.
In MJD patients, as well as other SCAs patients, the gait ataxia
is a clinical symptom always present. Indeed, gait difficulty is
reported as the initial symptom in 66% of the patients while for
others, symptoms like cramps (9%), sleep disturbances (5%),
neuropathic symptoms (3%), restless legs syndrome (3%) among
others appear first [34]. In this study the allele-specific silencing
was able to hamper the development and progression of gait
ataxia, as measured by the specific test of footprint analysis.
Furthermore, gene silencing mediated alleviation of the
hyperactive phenotype observed in this mouse model. Hyperac-
tivity had been already reported for a mouse model of
Dentatorubral-Pallidoluysian Atrophy (DRPLA) [46] and MJD
[47]. This phenotype can be an indication of reduced emotionality
[48] as observed in MJD patients [49]. However, other MJD
mouse models presented hypoactivity [32,50,51]. In fact, this
phenomenon can also be related to the restless legs syndrome and
REM sleep behavior disorder, which are more frequent in MJD
than other SCA patients (50%) [52,53].
Regarding neuropathology, mutant ataxin-3 silencing was also
able to reduce the mutant ataxin-3 aggregate formation and to
hamper the development of Purkinje cells abnormalities and
dysfunctional expression of neuronal markers, as observed in mice
treated with control sequences (shGFP). These neuropathological
findings correlate with the observed motor behavior effects and
with the previous results obtained with this strategy [18,19].
In summary, we show that early and permanent lentiviral-
mediated expression of RNAi sequences (shRNAs) targeting
mutant ataxin-3 can dramatically hamper the development of
MJD-associated abnormalities, including behavioral and neuro-
pathological deficits in a mouse model of MJD. Notwithstanding
the limitations of the experimental paradigm these data suggest
that early gene silencing prevents or delays disease progression.
Because genetic testing can be performed as early as in uterus, this
strategy might be of benefit in the future, and thus may constitute
a therapeutic strategy for MJD.
Materials and Methods
Lentiviral vectors
Viral vectors encoding for short-hairpin RNAs against GFP
(shGFP) and human mutant ataxin-3 (shAtx3), as well as human
full length mutant ataxin-3 with 72 glutamines (Atx3 MUT/
MUT) [18], were produced in human embryonic kidney (HEK)
293T cells using as four-plasmid system described previously [38].
The lentiviral particles produced were resuspended in phosphate-
buffered saline (PBS) with 0.5% bovine serum albumin (BSA) and
samples were matched for particle concentration by measuring
Figure 3. Allele-specific silencing of mutant ataxin-3 leads to diminution of the number of intranuclear aggregates. Confocal
microscopy of ataxin-3, b-galactosidase, with nuclei counterstained in blue (DAPI). Mice injected with mutant ataxin-3 and short-hairpin against GFP
(upper panel, MUT+ shGFP) exhibit aggregates of mutant ataxin-3 ((b,f), red, arrows) co-localizing with the short-hairpin RNA ((c,g), green, arrows);
whereas aggregates from mice injected with mutant ataxin-3 and short-hairpin against mutant ataxin-3 (lower panel, MUT+ shAtx3) practically do not
co-localize(l,p). This indicates that cells expressing the shRNA against mutant ataxin-3 do not display aggregates. Scale bar: 10 mm. (Q) Quantification
of the mean number of aggregates per section. Silencing of mutant ataxin-3 significantly decreased the presence of mutant ataxin-3 aggregates
(MUT+shAtx3) as compared to control (MUT+shGFP). Values are represented as mean 6 SEM. *Statistical significance (n= 6; ***P,0.001; Unpaired
Student’s t-test).
doi:10.1371/journal.pone.0100086.g003
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HIV-1 p24 antigen content (RETROtek, Gentaur, Belgium). Viral
stocks were stored at 280uC until use.
In vivo experiments
Animals. Mice C57/BL6 were housed in a temperature-
controlled room and maintained on a 12 h light/dark cycle. Food
and water were available ad libitum. Research with animals was
conducted by trained researchers in an approved animal facility
under protocol approved by ORBEA (orga˜o responsa´vel pelo
Bem-estar Animal). The experiments were carried out in
accordance with the European Community Council directive
(86/609/EEC) for the care and use of laboratory animals.
Stereotaxic surgery. Mice were anesthetized by intraperito-
neal injection of a mixture of ketamine (100 mg/kg) with xylazine
(10 mg/kg). Concentrated lentiviral stocks were thawed on ice and
resuspended by vortexing and particle content matched to
250’000 ng of p24/ml. Wild-type C57BL/6 mice received a
single injection of 6 ml of Atx3 MUT+ shGFP (n=7; 1:1) and Atx3
MUT+ shAtx3 (n=8; 1:1) at a rate of 0.25 ml/min by means of an
automatic injector (Stoelting Co., Wood Dale, IL, USA), at the
following coordinates: 21.6 mm rostral to lambda, 0.0 mm
midline, and 21.0 mm ventral to the skull surface, with the
mouth bar set at 23.3 [31]. After the injection, the syringe needle
was left in place for an additional 5 min to minimize backflow.
Motor behavior tests
Mice were trained on a battery of motor tests starting at P21–25
and performed every 2 weeks until 10 weeks. All tests were
performed in a dark room after 30 minutes of acclimatization.
Rotarod. The rotarod apparatus (Letica Scientific Instru-
ments, Panlab, Barcelona, Spain) was used to measure fore and
hind limb motor coordination and balance. Each mouse was
placed on the rotarod at a constant speed (5 rpm) for a maximum
of 5 min, and the latency to fall was recorded. Mice received four
trials per time point. After this test each mouse was placed again
on the rotarod but this time at an accelerated speed (4 to 40 rpm
in 5 min) for a maximum of 5 min, and the latency to fall was
recorded. Mice received four trials per time point. For analysis, the
mean latency to fall off the rotarod of 3–4 trials was used.
Footprint test. The footprint test was used to compare the
gait of shAtx3 and control- treated lentiviral MJD mice. To obtain
the footprints, the hind- and forefeet of the mice were coated with
black and green nontoxic paints, respectively. The animals were
then allowed to walk along a 100-cm-long, 10-cm-wide runaway
(with 15-cm high walls). A fresh sheet of white paper was placed on
the floor of the runaway for each mouse run. The footprint
patterns were analyzed for four step parameters (all measured in
centimeters). (1) Stride length was measured as the average
distance of forward movement between each stride. (2) Hind-base
width and (3) front-base width were measured as the average
distance between left and right hind footprints, respectively. These
values were determined by measuring the perpendicular distance
of a given step to a line connecting its opposite preceding and
proceeding steps. (4) Distance from left or right front footprint/
hind footprint overlap was used to measure uniformity of step
alternation. When the center of the hind footprint fell on top of the
center of the preceding front footprint, a value of zero was
recorded. When the footprints did not overlap, the distance
between the center of the footprints was recorded. A sequence of
six consecutive steps was chosen for evaluation, excluding
footprints made at the beginning and end of the run where the
animal was initiating and finishing movement, respectively. The
same operator made all footprints measurements blindly. The
mean value of each set of 5–6 values was used for analysis.
Open field analysis. For the assessment of the explorative
and general activity behavior, open field tests were performed.
Mice were placed in a 50650 cm arena with 50 cm high walls and
their movement activity was recorded for 40 min using the Acti-
Track System (Panlab, Barcelona, Spain). In the analysis, the first
10 min correspond to the exploratory behavior, the last 30 min to
the general activity of the mice, the periphery of the arena a
comfort and shelter zone and the center of the arena an insecure
zone.
Histological processing
Tissue preparation. Animals were killed by sodium pento-
barbital overdose, transcardially perfused with a 4% paraformal-
dehyde fixative solution (PFA 4%, Fluka, Sigma, St. Louis, USA)
followed by brain removal. After a cryoprotective incubation in
25% sucrose in 0.1 M PBS for 48 h, brains were frozen in dry ice
(280uC) and 20 mm coronal sections were cut at a cryostat-
microtome (Leica CM3050S, Leica Microsystems Nussloch,
Germany). Slices throughout the entire cerebellum were collected
in superfrost plus microscope slides (Thermo Fisher Scientific,
U.S.A.) and stored at 220uC before immunohistochemical
processing.
Immunohistochemical procedure. The immunohisto-
chemical procedure initiated with a 30 min dehydratation at
37uC followed by a 30 min hydration in 0.1 PBS and 1 h blocking
in a 0.3% triton in 0.1 PBS with 10% normal goat serum both at
room temperature (RT). The following primary antibodies diluted
in a blocking solution with 0.1% triton were used: mouse
monoclonal anti-ataxin-3 (1H9, Chemicon, Temecula, CA,
USA; 1:5000; 48 h, 4uC), rabbit polyclonal anti-b-galactosidase
(Molecular Probes, Invitrogen; 1:1000; 48 h, 4uC), rabbit poly-
clonal anti-DARPP-32 (Chemicon,Temecula, CA, USA; 1:5000,
48 h, 4uC), rabbit polyclonal anti-calbindin D-28K (Chemicon,-
Temecula, CA, USA; 1:1000, 48 h, 4uC). Sections were then
incubated in secondary antibody, goat-anti rabbit and/or mouse
conjugated to alexa 488 or 594 (Invitrogen) for 2 h/RT e and then
mounted in mowiol (Sigma) with 49,69-diamidino-2-phenylindole.-
Fluorescence images were acquired with a Zeiss Axiovert 200
imaging microscope or LSM Zeiss microscope for double staining
experiments.
Western blot. Mice cerebella were removed after a sodium
pentobarbital overdose, and incubated on ice in a radioimmuno-
Figure 4. Allele-specific silencing of mutant ataxin-3 reduced the levels of mutant protein and mRNA. (A) Western blot analysis of
cerebellar lysates stained with 1H9 antibody for ataxin-3. (B–D) Differences in the levels of high molecular weight protein species were detected
between animals co-injected with MUT+shAtx3 (n= 3) and animals control (co-injected with MUT+shGFP, n= 3), whereas no differences were found
in ataxin-3 endogenous levels. Normalization of protein levels was made with b-tubulin protein endogenous levels. (E) Quantitative real-time PCR
analysis of cerebelar lysates shows a reduction in the ataxin-3 mRNA levels in the animals co-injected with MUR+shAtx3 compared to controls.
Endogenous hprt mRNA was used as an internal control for the normalization and quantitative analysis of the ataxin-3 mRNA levels. Values are
represented as mean 6 SEM. *Statistical significance (n= 3; **P,0.01; ***P,0.001; Unpaired Student’s t-test).
doi:10.1371/journal.pone.0100086.g004
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precipitation assay-buffer solution (50 mM Tris HCl, pH 8,
150 nM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulphate) containing proteases inhibitors (Roche
diagnostics GmbH) followed by a 4 sec ultra-sound pulse (1 pulse/
sec). Total protein lysates were stored at 280uC, protein
concentration was determined with the Bradford protein assay
(BioRad), and 30 mg of protein extract was resolved in sodium
dodecyl sulphate-polyacrylamide gels (4% stacking and 10%
running). The proteins were transferred onto polyvinylidene
difluoride membranes (GE Healthcare) according to standard
protocols. The immunobloting procedure was performed as
described previously [11] with the respective primary antibody
(1H9, Chemicon, Temecula, CA, USA; 1:5000), followed by
incubation wit the corresponding alkaline phosphatase-linked
secondary antibody. Bands were visualized with Enhanced
Chemifluorescence substrate (ECF, GE Healthcare) and chemi-
fluorescence imaging (VersaDoc Imaging System Model 3000,
Bio-Rad). Membranes were stripped using 0.1 M glycine pH 2.3
(30 min, room temperature) and reprobed with mouse monoclonal
anti-b-actin antibody (1:5000, Sigma). Densitometric analysis was
carried out in the same gel using Image J software (NIH, USA).
RT-PCR analysis. Mice cerebella were removed after a
sodium pentobarbital overdose, and the cerebelar cortex was
stored at 280uC for posterior RNA extraction. Total RNA was
extracted using the RNeasy Mini Kit following the manufacturer’s
instructions (Qiagen, CA, USA). Real-time quantitative RT-PCR
was performed in duplicate for each sample with 0.4% random-
primed cDNAs generated from 400 ng total RNA. PCR was
carried out in a 15 ml reaction volume containing SYBR Green
Fast (Bio-Rad), and 100 nM of QuantiTect Primer Assay for
human ataxin-3 (QT00094927, Qiagen, CA, USA). An Applied
Biosystems, Step One Plus thermal cycler was programmed for an
initial denaturation step (95uC, 30 sec) followed by 45 amplifica-
tion cycles (95uC, 5 sec; 55uC, 15 sec). The amplification rate for
each target was evaluated from the cycle threshold (Ct) numbers
obtained with cDNA dilutions, with corrections for mouse hprt
levels (QuantiTect Primer Assay, QT00166768; Qiagen, CA,
USA), which were assumed to be constant. Differences between
control and experimental samples were calculated using the
22DDCt method [54].
Quantification of nuclear inclusions and neuronal
markers expression. Quantification of ataxin-3 positive in-
clusions was performed blindly by scanning 4 coronal sections
spread over the anterior-posterior extent of the cerebellum (inter-
section distance: 240 mm), using a 206 objective on a Zeiss
Axiovert 200 imaging microscope and an image acquisition and
analysis software (ImageJ, NIH). For each coronal section and
animal 8 fields were acquired, covering the same areas. The
average number of inclusions in the cerebellum was calculated for
each animal. The quantification of DARPP-32 and calbindin
neuronal expression was performed blindly by scanning 4 coronal
sections spread over the anterior-posterior extent of the cerebellum
expressing the mutant ataxin-3 protein (inter-section distance:
240 mm), using a 406 and 206objective on a Zeiss Axiovert 200
imaging microscope. For each coronal section and animal, 8 fields
were acquired using the same exposure and covering the same
areas. Optical densitometry analysis was performed using Image
analysis software (ImageJ, National Intistute of Health, U.S.A).
Cerebellar regions expressing DARPP-32/calbindin revealed to
have an increased optical density value when compared to regions
not expressing the protein. Values are represented as the mean
value of DARPP-32/Calbindin optical density per section 6 SEM
(arbitrary units).
Cresyl violet staining. Coronal brain sections were stained
with cresyl violet dye for 2 minutes, differentiated in acetate buffer
pH 3.8 (2.72% sodium acetate and 1.2% acetic acid; 1:4 v/v),
dehydrated by passing twice through ethanol and toluol solutions,
and mounted with EukittH (O. Kindler GmbH & CO. Freiburg,
Germany).
Quantification of Purkinje cell number and molecular
and granular layers size. Quantification of the number of
Purkinje cells was performed blindly by scanning 4 coronal
sections spread over the anterior-posterior extent of the cerebellum
(inter-section distance: 240 mm), using a 206 objective on a Zeiss
Axiovert 200 imaging microscope and image analysis software
(Image J, NIH). For each coronal section and animal, 6 fields
covering the same cerebellar regions were acquired, and Purkinje
cells counted in those images. For the cerebellar layers sizes, for
each acquired field at least 6 measurements were made blindly in
the same region for all animals, and results converted to mm using
Image J software (NIH). Values are represented as the mean
number of Purkinje cells per 100 mm 6 SEM.
TUNEL assay. Cerebellar sections were stained using the In
situ cell death detection kit, TMR Red (Roche, Mannheim,
Germany) following the supplier’s manual, which detects apoptotic
cell death. The images were acquired digitally using a 406
objective on a Zeiss Axiovert 200 imaging microscope. All
photographs for comparison were taken under identical image
acquisition conditions and uniform adjustments of brightness and
contrast were made to all images.
Fluorojade-B staining. Cerebellar sections were stained
with FluoroJade-B (Chemicon, Temecula, CA), an anionic
fluorescein derivative that stains neurons undergoing degenera-
tion. The sections were mounted on glass slides, dehydrated, and
stained according to the supplier’s manual. The images were
acquired using a Zeiss Axiovert 200 imaging microscope. All
photographs for comparison were taken under identical image
acquisition conditions and uniform adjustments of brightness and
contrast.
Golgi staining. Golgi neurohistological staining was per-
formed following a modification of classical Golgi procedure
described previously [55].
Figure 5. Allele-specific silencing prevents Purkinje cells pathology. Fluorescence microscopy analysis for the DARPP-32 (a,b) and calbindin
(c,d) proteins highlighting the Purkinje cells. An increased expression of DARPP-32 neuronal marker was observed for the shAtx3-treated mice,
relative to control-treated. Note the improved Purkinje cell morphology in shAtx3-treated mice (arrows) as compared to shrunken-sized Purkinje cells
in control-treated (arrow heads). Scale bar: 40 mm. (E) Quantification of optical densitometry of DARPP-32 immunoreactivity. Silencing of mutant
ataxin-3 significantly increased DARPP-32 expression (MUT+shAtx3) as compared to control (MUT+ shGFP). *Statistical significance (n= 5; ***P,0.001;
Unpaired Student’s t-test). (f–i) Fluorescence microscopy analysis for the calbindin protein highlighting the Purkinje cells and the molecular layer (c,d).
An increased expression of calbindin neuronal marker was observed for the shAtx3-treated mice (d), relative to control-treated (c). Note the improved
Purkinje cell morphology in shAtx3-treated mice and increased expression of calbindin in the molecular layer as compared to control. Scale bar:
40 mm. (F) Quantification of optical densitometry of calbindin immunoreactivity. *Statistical significance (n= 5; **P,0.01; Unpaired Student’s t-test).
doi:10.1371/journal.pone.0100086.g005
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